Study With [225Ac]Ac-FL-020 in mCRPC Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

[225Ac]Ac-FL-020

\[225Ac\]Ac-FL-020 injected intravenously

DRUG

Blood samples for PK

Following the first injection of \[225Ac\]Ac-FL-020, blood samples after treatment will be collected for PK evaluation.

DRUG

[111In]In-FL-020

A dose of \[111In\]In-FL-020 will be injected prior to the first dose of \[225Ac\]Ac-FL-020 for dosimetry evaluation

PROCEDURE

Blood and urine samples collection

For dosimetry evaluation and urine excretion assessment, blood and urine samples will be collected after the injection of \[111In\]In-FL-020

PROCEDURE

SPECT/CT images

For dosimetry evaluation, SPECT/CTs will be performed following the injection of \[111In\]In-FL-020.

Trial Locations (6)

91010

RECRUITING

City of Hope Medical Center, Duarte

92612

RECRUITING

Chao Family Comprehensive Cancer Center, Irvine

94305

RECRUITING

University of Stanford, Stanford

Unknown

RECRUITING

Princess Alexandra Hospital, Brisbane

RECRUITING

Genesiscare Murdoch, Murdoch

NSW 2109

RECRUITING

MacQuarie University Clinical Trial Unit, Sydney

Sponsors
All Listed Sponsors
lead

Full-Life Technologies GmbH

INDUSTRY